Karuna Therapeutics Appoints David Wheadon, M.D., to Its Board of Directors
December 03 2020 - 9:17AM
Business Wire
Ed Harrigan, M.D., to step down from Karuna’s
board and continue to serve on the Company’s scientific advisory
board
Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative
clinical-stage biopharmaceutical company committed to developing
novel therapies with the potential to transform the lives of people
with disabling and potentially fatal neuropsychiatric disorders,
today announced the appointment of David Wheadon, M.D., to its
Board of Directors. In addition, the Company announced that Ed
Harrigan, M.D., will step down from the Board of Directors
effective December 3, 2020. Dr. Harrigan will continue to serve as
a member of the Company’s scientific advisory board.
“We are thrilled to welcome David to our Board of Directors,”
said Steve Paul, M.D., chief executive officer, president and
chairman of Karuna Therapeutics. “David is a distinguished
pharmaceutical leader with an extensive background in regulatory
affairs, global health policy and clinical strategy. His successful
track record in drug development, including several important
neuropsychiatric medicines, provides an invaluable perspective as
Karuna advances to late-stage clinical development and continues to
grow a pipeline of novel neuropsychiatric therapies.”
“I am proud to join the board of Karuna and work alongside a
passionate team that is uniquely steeped in neuroscience, with
first-hand experience developing medicines for those living with
disabling psychiatric disorders,” stated Dr. Wheadon. “Karuna is
entering an exciting phase in neuropsychiatric drug development,
and I look forward to contributing to the Company’s efforts in
delivering meaningful treatment advancements for those affected by
psychiatric and neurological conditions.”
Dr. Wheadon is a trained physician and psychiatrist with more
than 30 years of industry experience in clinical development,
public policy and regulatory affairs. Most recently Dr. Wheadon
served as Senior Vice President, Global Regulatory Affairs, Patient
Safety and Quality Assurance at AstraZeneca Pharmaceuticals. Prior
to AstraZeneca, he held senior regulatory and clinical development
leadership positions at Abbott, GlaxoSmithKline, Eli Lilly, the
Juvenile Diabetes Research Foundation and the Pharmaceutical
Research and Manufacturers of America (PhRMA). Dr. Wheadon is a
board member of Assertio Holdings, Inc. He holds an A.B. in biology
from Harvard College and an M.D. from Johns Hopkins University
School of Medicine. He completed his fellowship training in
psychiatry at Tufts New England Medical Center.
“Ed has provided invaluable guidance and contributions to the
clinical and corporate growth of Karuna since joining shortly after
the Company’s inception,” stated Dr. Paul. “The Karuna board and
management team extend our profound thanks to Ed for his leadership
during these instrumental and formative years, and we look forward
to our continued partnership with Ed as a member of our scientific
advisory board.”
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed
to developing and delivering first-in-class therapies with the
potential to transform the lives of people with CNS disorders –
which remain among the most disabling and potentially fatal
disorders worldwide. Galvanized by the understanding that today’s
neuropsychiatric patients deserve better, Karuna’s mission is to
harness the untapped potential of the brain’s complex biology in
pursuit of novel therapeutic pathways that will advance the
standard of care. For more information, please visit
karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding our expectations about the
timing of advancing of our planned clinical trials and regulatory
filings, our goals to develop and commercialize our product
candidates, our identification of additional product candidates,
and other statements identified by words such as “could,”
“expects,” “intends,” “may,” “plans,” “potential,” “should,”
“will,” “would,” or similar expressions and the negatives of those
terms. Forward-looking statements are not promises or guarantees of
future performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to obtain necessary funding, our ability to generate positive
clinical trial results for our product candidates, the timing and
scope of regulatory approvals, changes in laws and regulations to
which we are subject, competitive pressures, our ability to
identify additional product candidates, risks relating to business
interruptions resulting from the coronavirus (COVID-19) pandemic,
and other risks set forth under the heading “Risk Factors” of our
Annual Report on Form 10-K for the year ended December 31, 2019 and
our Quarterly Report on Form 10-Q for the quarter ended September
30, 2020. Our actual results could differ materially from the
results described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005618/en/
Investor Contact Alexis Smith 518-338-8990
asmith@karunatx.com
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024